# A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma

> **NCT00554372** · PHASE2 · COMPLETED · sponsor: **Jennerex Biotherapeutics** · enrollment: 30 (actual)

## Conditions studied

- Carcinoma, Hepatocellular

## Interventions

- **GENETIC:** JX-594: Recombinant vaccinia virus (TK-deletion plus GM-CSF)

## Key facts

- **NCT ID:** NCT00554372
- **Lead sponsor:** Jennerex Biotherapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2011-12
- **Final completion:** 2013-02
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2016-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00554372

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00554372, "A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00554372. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*